Clinical trial
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
NCT04844918 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT04844918 |
|---|---|
| Title | A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease |
| Official title | Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J) |
| Acronym | SURMOUNT-J |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug, Other |
| Interventions | Tirzepatide, Placebo |
| Enrollment | 267 |
| Start date | May 10, 2021 |
| Primary completion | Jun 24, 2023 |
| Completion | Jun 24, 2023 |
| First posted | Apr 14, 2021 |
| Last update posted | Jul 16, 2024 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: